KYORIN Holdings Inc (4569):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:KYORIN Holdings Inc (4569) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C12398
◆発行会社(調査会社):GlobalData
◆発行日:2018年12月
◆ページ数:39
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:日本
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
KYORIN Holdings Inc (KYORIN), formerly known as KYORIN Co.,Ltd., is a holding company. Its business activities include controlling, administering and supporting companies, which conduct various businesses by holding the shares of those companies. The company through its subsidiaries carries out the discovery, manufacturing and sale of pharmaceuticals including new ethical drugs, generic drugs and the over-the-counter (OTC) drugs. It also provides consumer healthcare products including beauty and good health products. KYORIN provides product under Kipres, Mucodyne, Pentasa, Uritos, Ketas, Flutiform, Milton, Rubysta and other brands. KYORIN is headquartered in Chiyoda-Ku, Tokyo, Japan.

KYORIN Holdings Inc (4569) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
KYORIN Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Kyorin Acquires Production Facility from MSD 11
Partnerships 12
Kyorin Pharma Enters into Collaborative Agreement with Microbial Chemistry Research Foundation 12
Kyorin Pharma Enters into Development and Distribution Agreement with Faes Farma 13
MSD Enters into Distribution Agreement with Kyorin Pharma 14
MSD Enters into Agreement with Kyorin Pharma 15
Kyorin Pharma to Enter into Co-Promotion Agreement with Kaken Pharma 16
Kissei Pharma Enters into Agreement with Kyorin Pharma 17
Kyorin Pharma Enters into Co-Development Agreement with PeptiDream 18
Kyorin Pharma Enters into Co-Marketing Agreement with Yoshida Pharma 19
Kyorin Pharma Amends Co-Marketing Agreement with MSD 20
Eisai Enters into Agreement with Kyorin 21
Kyorin Pharma Enters Into Research Agreement With BioLeap 22
Licensing Agreements 23
Kyorin Pharma Enters into Licensing Agreement with Sanwa Kagaku 23
KYORIN Rimedio Enters into a Licensing Agreement with Binh Dinh Pharma 24
Kyorin Pharma Enters into Licensing Agreement with Merck 25
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 26
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 27
Synmosa Biopharma Enters into Licensing Agreement with Kyorin Pharma 28
R-Pharm Enters into Licensing Agreement with Kyorin Pharma for Imidafenacin 29
Kyorin Pharma Enters into Licensing Agreement with Merck 30
Asset Transactions 31
Galderma Acquires Pekiron Cream From Kyorin Pharma 31
Acquisition 32
Taisho Pharma to Acquire Dr. Program from Kyorin Pharma 32
Teijin Acquires 10% Stake In Kyorin For US$197 Million 33
KYORIN Holdings Inc – Key Competitors 34
KYORIN Holdings Inc – Key Employees 35
KYORIN Holdings Inc – Locations And Subsidiaries 36
Head Office 36
Other Locations & Subsidiaries 36
Recent Developments 37
Other Significant Developments 37
Jun 06, 2017: PeptiDream Announces First Milestone from Macrocyclic Peptide Drug Discovery Alliance with Kyorin 37
Feb 22, 2017: Kyorin Holdings: Establishment of a Representative Office in the Republic of Indonesia 38
Appendix 39
Methodology 39
About GlobalData 39
Contact Us 39
Disclaimer 39

List of Tables
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
KYORIN Holdings Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
KYORIN Holdings Inc, Deals By Therapy Area, 2012 to YTD 2018 8
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Kyorin Acquires Production Facility from MSD 11
Kyorin Pharma Enters into Collaborative Agreement with Microbial Chemistry Research Foundation 12
Kyorin Pharma Enters into Development and Distribution Agreement with Faes Farma 13
MSD Enters into Distribution Agreement with Kyorin Pharma 14
MSD Enters into Agreement with Kyorin Pharma 15
Kyorin Pharma to Enter into Co-Promotion Agreement with Kaken Pharma 16
Kissei Pharma Enters into Agreement with Kyorin Pharma 17
Kyorin Pharma Enters into Co-Development Agreement with PeptiDream 18
Kyorin Pharma Enters into Co-Marketing Agreement with Yoshida Pharma 19
Kyorin Pharma Amends Co-Marketing Agreement with MSD 20
Eisai Enters into Agreement with Kyorin 21
Kyorin Pharma Enters Into Research Agreement With BioLeap 22
Kyorin Pharma Enters into Licensing Agreement with Sanwa Kagaku 23
KYORIN Rimedio Enters into a Licensing Agreement with Binh Dinh Pharma 24
Kyorin Pharma Enters into Licensing Agreement with Merck 25
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 26
Bristol-Myers Squibb Enters into Licensing Agreement with Kyorin Pharma 27
Synmosa Biopharma Enters into Licensing Agreement with Kyorin Pharma 28
R-Pharm Enters into Licensing Agreement with Kyorin Pharma for Imidafenacin 29
Kyorin Pharma Enters into Licensing Agreement with Merck 30
Galderma Acquires Pekiron Cream From Kyorin Pharma 31
Taisho Pharma to Acquire Dr. Program from Kyorin Pharma 32
Teijin Acquires 10% Stake In Kyorin For US$197 Million 33
KYORIN Holdings Inc, Key Competitors 34
KYORIN Holdings Inc, Key Employees 35
KYORIN Holdings Inc, Subsidiaries 36

List of Figures
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
KYORIN Holdings Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[KYORIN Holdings Inc (4569):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Lea County Electric Cooperative Inc:企業の戦略的SWOT分析
    Lea County Electric Cooperative Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Smartac Group China Holdings Ltd (395):企業の財務・戦略的SWOT分析
    Smartac Group China Holdings Ltd (395) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Shangri-La Hotels (Malaysia) Berhad:戦略・SWOT・企業財務分析
    Shangri-La Hotels (Malaysia) Berhad - Strategy, SWOT and Corporate Finance Report Summary Shangri-La Hotels (Malaysia) Berhad - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Central National Gottesman Inc:企業の戦略・SWOT・財務分析
    Central National Gottesman Inc - Strategy, SWOT and Corporate Finance Report Summary Central National Gottesman Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Kalpataru Power Transmission Ltd:企業の戦略・SWOT・財務情報
    Kalpataru Power Transmission Ltd - Strategy, SWOT and Corporate Finance Report Summary Kalpataru Power Transmission Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, produ …
  • Empresa Electrica Corani SA (COR1U):電力:M&Aディール及び事業提携情報
    Summary Empresa Electrica Corani SA (Empresa Electrica), a subsidiary of Empresa Nacional de Electricidad Bolivia, is a renewable energy company that develops and operates hydroelectric power plants and wind farms. The company offers operation and maintenance, project development, and technical serv …
  • KENKO Mayonnaise Co Ltd:企業の戦略・SWOT・財務分析
    KENKO Mayonnaise Co Ltd - Strategy, SWOT and Corporate Finance Report Summary KENKO Mayonnaise Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Chi Mei Corp:企業の戦略的SWOT分析
    Chi Mei Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • Municipal Energy Agency of Nebraska:企業の戦略的SWOT分析
    Municipal Energy Agency of Nebraska - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Taita Chemical Co, Ltd (1309):企業の財務・戦略的SWOT分析
    Taita Chemical Co, Ltd (1309) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • Dechra Pharmaceuticals PLC:企業のM&A・事業提携・投資動向
    Dechra Pharmaceuticals PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Dechra Pharmaceuticals PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Al Mouwasat Medical Services Company (4002):企業の財務・戦略的SWOT分析
    Summary Al Mouwasat Medical Services Company (Mouwasat Medical) is a healthcare service provider that provides health and skincare services. The centre offers services in health care, skin care, and fertility treatment. It provides clinical pharmacy services such as verifying dosages appropriateness …
  • Engie SA (ENGI)-エネルギー分野:企業M&A・提携分析
    Summary Engie S.A. (Engie), formerly GDF Suez S.A., is an electric utility, which generates and distributes electricity and natural gas. It generates electricity using various sources including hydro, wind, solar, biomass, geothermal, nuclear, coal and fuel oil. The company supplies, distributes, tr …
  • China Grand Pharmaceutical and Healthcare Holdings Ltd (512):企業の財務・戦略的SWOT分析
    Summary China Grand Pharmaceutical and Healthcare Holdings Ltd (China Grand) is an investment holding company that develops, manufacture and distributes pharmaceutical preparations, medical devices and pharmaceutical intermediates, specialized raw materials, and healthcare products. The company prov …
  • Voyager Therapeutics Inc (VYGR):企業の財務・戦略的SWOT分析
    Summary Voyager Therapeutics Inc (Voyager) is a gene therapy company that discovers, develops and commercializes therapies to treat severe neurological diseases. It is evaluating VY-AADC program for the treatment of advanced Parkinson’s disease; VY-SOD102 against monogenic amyotrophic lateral sclero …
  • Diebold Nixdorf Inc (DBD):企業の財務・戦略的SWOT分析
    Diebold Nixdorf Inc (DBD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Samsung Fire & Marine Insurance Co., Ltd.:企業の戦略・SWOT・財務情報
    Samsung Fire & Marine Insurance Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Samsung Fire & Marine Insurance Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SW …
  • Lloyds Banking Group Plc:企業の戦略・SWOT・財務分析
    Lloyds Banking Group Plc - Strategy, SWOT and Corporate Finance Report Summary Lloyds Banking Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Mindax Limited:企業の戦略・SWOT・財務情報
    Mindax Limited - Strategy, SWOT and Corporate Finance Report Summary Mindax Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • Co-Diagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Co-Diagnostics Inc (Co-Diagnostics) is a molecular diagnostics company that develops, manufactures and markets a state-of-the-art diagnostics technology. The company’s products include HCV RNA real-time PCR kit, HIV RNA real-time PCR kit, malaria DNA real-time PCR kit, and TB complex DNA kit …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆